Opthea (ASX:OPT) EV-to-Revenue

: 1,121.17 (As of Today)

View and export this data going back to 1991. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Opthea's enterprise value is A$195.08 Mil. Opthea's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.17 Mil. Therefore, Opthea's EV-to-Revenue for today is 1,121.17.

The historical rank and industry rank for Opthea's EV-to-Revenue or its related term are showing as below:

ASX:OPT' s EV-to-Revenue Range Over the Past 10 Years
Min: 355.58 Med: 1686.62 Max: 5243.61
Current: 1121.16

During the past 13 years, the highest EV-to-Revenue of Opthea was 5243.61. The lowest was 355.58. And the median was 1686.62.

ASX:OPT's EV-to-Revenue is ranked worse than
95.54% of 1032 companies
in the Biotechnology industry
Industry Median: 7.825 vs ASX:OPT: 1121.16

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-16), Opthea's stock price is A$0.66. Opthea's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, Opthea's PS Ratio for today is .

Opthea EV-to-Revenue Historical Data

The historical data trend for Opthea's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-Revenue

902.68

6,749.13

3,490.44

2,510.53

772.14

Opthea Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue																-	2,510.53	-	772.14	-

Competitive Comparison

For the Biotechnology subindustry, Opthea's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Opthea's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Opthea's EV-to-Revenue falls into.

Opthea EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Opthea's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	195.083	/	0.174
	=	1,121.17

Opthea's current Enterprise Value is A$195.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Opthea's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.17 Mil.

Opthea (ASX:OPT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Opthea's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.66	/	0
	=

Opthea's share price for today is A$0.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

Opthea EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Opthea's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea (ASX:OPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.